Peptides Similar to Albiglutide (Tanzeum)
Compare Albiglutide (Tanzeum) with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semaglutide: High - Both are once-weekly GLP-1 receptor agonists for type 2 diabetes with proven cardiovascular benefit
- •Liraglutide: High - Both are GLP-1 receptor agonists with proven cardiovascular benefit, though liraglutide requires daily injection
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Albiglutide (Tanzeum) (current) | - | - |
| Semaglutide | High - Both are once-weekly GLP-1 receptor agonists for type 2 diabetes with proven cardiovascular benefit | Semaglutide uses C18 fatty diacid acylation (4.1 kDa) while albiglutide used albumin fusion (72.9 kDa). Semaglutide has substantially greater HbA1c reduction, weight loss, and an oral formulation. |
| Liraglutide | High - Both are GLP-1 receptor agonists with proven cardiovascular benefit, though liraglutide requires daily injection | Liraglutide uses C16 fatty acid acylation with once-daily dosing. Albiglutide was once-weekly but less effective. Liraglutide was statistically superior to albiglutide in the HARMONY 7 head-to-head trial. |
| Taspoglutide | Moderate - Both were once-weekly GLP-1 agonists that ultimately failed, though for different reasons | Taspoglutide used a zinc-depot formulation with much higher efficacy but severe GI toxicity and immunogenicity. Albiglutide had better tolerability but insufficient efficacy. Taspoglutide never reached approval. |
SemaglutideHigh - Both are once-weekly GLP-1 receptor agonists for type 2 diabetes with proven cardiovascular benefit
Differences
Semaglutide uses C18 fatty diacid acylation (4.1 kDa) while albiglutide used albumin fusion (72.9 kDa). Semaglutide has substantially greater HbA1c reduction, weight loss, and an oral formulation.
Advantages
Semaglutide has superior efficacy for glycemic control and weight loss, three approved formulations (SC weekly, oral daily, higher-dose for obesity), proven CV benefit in SELECT, and continued commercial success
Disadvantages
Semaglutide has higher GI side effect rates (nausea 15-44% vs 10-12%) due to greater pharmacological potency
LiraglutideHigh - Both are GLP-1 receptor agonists with proven cardiovascular benefit, though liraglutide requires daily injection
Differences
Liraglutide uses C16 fatty acid acylation with once-daily dosing. Albiglutide was once-weekly but less effective. Liraglutide was statistically superior to albiglutide in the HARMONY 7 head-to-head trial.
Advantages
Liraglutide has greater HbA1c reduction and weight loss, proven CV benefit (LEADER), pediatric approval for obesity, extensive real-world experience over a decade of use
Disadvantages
Requires daily injection versus albiglutide's weekly dosing; being gradually superseded by weekly GLP-1 agonists; higher GI side effect rates than albiglutide
TaspoglutideModerate - Both were once-weekly GLP-1 agonists that ultimately failed, though for different reasons
Differences
Taspoglutide used a zinc-depot formulation with much higher efficacy but severe GI toxicity and immunogenicity. Albiglutide had better tolerability but insufficient efficacy. Taspoglutide never reached approval.
Advantages
Albiglutide reached FDA approval and demonstrated CV benefit in HARMONY Outcomes; much better tolerability profile
Disadvantages
Albiglutide was commercially unsuccessful and withdrawn; required complex reconstitution; lower efficacy than all marketed GLP-1 agonists
Peptides Related to Albiglutide#
Albiglutide (Tanzeum) was one of several once-weekly GLP-1 receptor agonists developed for type 2 diabetes. Its withdrawal from the market in 2017 due to commercial failure reflects the intense competition in this therapeutic class, where superior efficacy ultimately determined commercial success.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide is the most commercially successful GLP-1 receptor agonist and represents the standard against which albiglutide's limitations are most apparent. While both achieved once-weekly dosing, their molecular strategies differed fundamentally: albiglutide used albumin fusion (72.9 kDa), while semaglutide uses C18 fatty diacid acylation (4.1 kDa). The smaller, more potent semaglutide achieves greater HbA1c reduction (-1.5 to -2.2% vs -0.6 to -0.8%) and weight loss, with the added advantage of an oral formulation (Rybelsus) and a high-dose obesity indication (Wegovy).
Liraglutide (Victoza / Saxenda)#
Liraglutide was the GLP-1 agonist that most directly contributed to albiglutide's commercial failure. In the HARMONY 7 head-to-head trial, once-weekly albiglutide 50 mg failed to demonstrate non-inferiority to once-daily liraglutide 1.8 mg for HbA1c reduction. This result meant that albiglutide's key selling point (weekly dosing) was insufficient to overcome its efficacy disadvantage against a daily competitor.
Taspoglutide#
Taspoglutide represents the opposite failure mode from albiglutide. While albiglutide failed due to insufficient efficacy, taspoglutide failed due to excessive toxicity. Taspoglutide achieved superior HbA1c reduction (-1.24 to -1.31%) but was terminated in 2010 due to severe nausea (53-59%), vomiting (33-37%), and 49% immunogenicity.
Summary Comparison#
| Feature | Albiglutide | Semaglutide | Liraglutide | Taspoglutide |
|---|---|---|---|---|
| Dosing | Weekly SC | Weekly SC / Daily oral | Daily SC | Weekly SC |
| HbA1c reduction | -0.6 to -0.8% | -1.5 to -2.2% | -1.1 to -1.2% | -1.24 to -1.31% |
| Nausea rate | 10-12% | 15-44% | 20-39% | 53-59% |
| CV outcomes | Positive (HR 0.78) | Positive | Positive | Not tested |
| Regulatory status | Approved then withdrawn | Approved | Approved | Terminated |
Comparison Context#
Albiglutide (Tanzeum) belongs to the Metabolic category of research peptides. Comparing Albiglutide (Tanzeum) with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Albiglutide (Tanzeum) in mechanism, indication, or therapeutic category:
Albiglutide (Tanzeum) vs Semaglutide#
Similarity: High - Both are once-weekly GLP-1 receptor agonists for type 2 diabetes with proven cardiovascular benefit
Key Differences: Semaglutide uses C18 fatty diacid acylation (4.1 kDa) while albiglutide used albumin fusion (72.9 kDa). Semaglutide has substantially greater HbA1c reduction, weight loss, and an oral formulation.
Advantages of Semaglutide: Semaglutide has superior efficacy for glycemic control and weight loss, three approved formulations (SC weekly, oral daily, higher-dose for obesity), proven CV benefit in SELECT, and continued commercial success
Disadvantages of Semaglutide: Semaglutide has higher GI side effect rates (nausea 15-44% vs 10-12%) due to greater pharmacological potency
Researchers choosing between Albiglutide (Tanzeum) and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Albiglutide (Tanzeum) vs Liraglutide#
Similarity: High - Both are GLP-1 receptor agonists with proven cardiovascular benefit, though liraglutide requires daily injection
Key Differences: Liraglutide uses C16 fatty acid acylation with once-daily dosing. Albiglutide was once-weekly but less effective. Liraglutide was statistically superior to albiglutide in the HARMONY 7 head-to-head trial.
Advantages of Liraglutide: Liraglutide has greater HbA1c reduction and weight loss, proven CV benefit (LEADER), pediatric approval for obesity, extensive real-world experience over a decade of use
Disadvantages of Liraglutide: Requires daily injection versus albiglutide's weekly dosing; being gradually superseded by weekly GLP-1 agonists; higher GI side effect rates than albiglutide
Researchers choosing between Albiglutide (Tanzeum) and Liraglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Albiglutide (Tanzeum) vs Taspoglutide#
Similarity: Moderate - Both were once-weekly GLP-1 agonists that ultimately failed, though for different reasons
Key Differences: Taspoglutide used a zinc-depot formulation with much higher efficacy but severe GI toxicity and immunogenicity. Albiglutide had better tolerability but insufficient efficacy. Taspoglutide never reached approval.
Advantages of Taspoglutide: Albiglutide reached FDA approval and demonstrated CV benefit in HARMONY Outcomes; much better tolerability profile
Disadvantages of Taspoglutide: Albiglutide was commercially unsuccessful and withdrawn; required complex reconstitution; lower efficacy than all marketed GLP-1 agonists
Researchers choosing between Albiglutide (Tanzeum) and Taspoglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Albiglutide (Tanzeum)
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer